Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
Pharmacoeconomics
.
2015 Aug;33(8):879-82.
doi: 10.1007/s40273-015-0278-7.
Authors
Jeffrey S Hoch
1
,
Jaclyn Beca
,
Mona Sabharwal
,
Scott W Livingstone
,
Anthony L A Fields
Affiliation
1
Centre for Excellence in Economic Analysis Research (CLEAR), Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada, jeffrey.hoch@utoronto.ca.
PMID:
25939500
PMCID:
PMC4519630
DOI:
10.1007/s40273-015-0278-7
No abstract available
Publication types
Letter
MeSH terms
Antineoplastic Agents / economics
Antineoplastic Agents / therapeutic use*
Canada
Humans
Neoplasms / drug therapy*
Neoplasms / economics
Technology Assessment, Biomedical / methods*
Substances
Antineoplastic Agents